BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 15608078)

  • 21. Novel nonimidazole histamine H3 receptor antagonists: 1-(4-(phenoxymethyl)benzyl)piperidines and related compounds.
    Mikó T; Ligneau X; Pertz HH; Ganellin CR; Arrang JM; Schwartz JC; Schunack W; Stark H
    J Med Chem; 2003 Apr; 46(8):1523-30. PubMed ID: 12672253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Importance of the lipophilic group in carbamates having histamine H3-receptor antagonist activity.
    Kieć-Kononowicz K; Wiecek M; Sasse A; Ligneau X; Elz S; Ganellin CR; Schwartz JC; Stark H; Schunack W
    Pharmazie; 2000 May; 55(5):349-55. PubMed ID: 11828613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of trans-2-[1H-imidazol-4-yl] cyclopropane derivatives as new high-affinity histamine H3 receptor ligands.
    Tedford CE; Phillips JG; Gregory R; Pawlowski GP; Fadnis L; Khan MA; Ali SM; Handley MK; Yates SL
    J Pharmacol Exp Ther; 1999 May; 289(2):1160-8. PubMed ID: 10215700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structurally novel histamine H3 receptor antagonists GSK207040 and GSK334429 improve scopolamine-induced memory impairment and capsaicin-induced secondary allodynia in rats.
    Medhurst AD; Briggs MA; Bruton G; Calver AR; Chessell I; Crook B; Davis JB; Davis RP; Foley AG; Heslop T; Hirst WD; Medhurst SJ; Ociepka S; Ray A; Regan CM; Sargent B; Schogger J; Stean TO; Trail BK; Upton N; White T; Orlek B; Wilson DM
    Biochem Pharmacol; 2007 Apr; 73(8):1182-94. PubMed ID: 17276409
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Search for novel leads for histamine H3-receptor antagonists: amine derivatives.
    Stark H; Ligneau X; Lipp R; Arrang JM; Schwartz JC; Schunack W
    Pharmazie; 1997 Jun; 52(6):419-23. PubMed ID: 9260265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of multiple H3 receptor affinity states utilizing [3H]A-349821, a novel, selective, non-imidazole histamine H3 receptor inverse agonist radioligand.
    Witte DG; Yao BB; Miller TR; Carr TL; Cassar S; Sharma R; Faghih R; Surber BW; Esbenshade TA; Hancock AA; Krueger KM
    Br J Pharmacol; 2006 Jul; 148(5):657-70. PubMed ID: 16715122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histamine H3-receptor-mediated [35S]GTP gamma[S] binding: evidence for constitutive activity of the recombinant and native rat and human H3 receptors.
    Rouleau A; Ligneau X; Tardivel-Lacombe J; Morisset S; Gbahou F; Schwartz JC; Arrang JM
    Br J Pharmacol; 2002 Jan; 135(2):383-92. PubMed ID: 11815373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of histamine H3 receptor antagonistic property of simple imidazole-free derivatives: Preliminary pharmacological investigation.
    Barocelli E; Ballabeni V; Manenti V; Flammini L; Bertoni S; Morini G; Comini M; Impicciatore M
    Pharmacol Res; 2006 Mar; 53(3):226-32. PubMed ID: 16364652
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological analysis of G-protein activation mediated by guinea-pig recombinant 5-HT1B receptors in C6-glial cells: similarities with the human 5-HT1B receptor.
    Pauwels PJ; Wurch T; Palmier C; Colpaert FC
    Br J Pharmacol; 1998 Jan; 123(1):51-62. PubMed ID: 9484854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the receptor selectivity of the H3 receptor antagonists, iodophenpropit and thioperamide: an interaction with the 5-HT3 receptor revealed.
    Leurs R; Tulp MT; Menge WM; Adolfs MJ; Zuiderveld OP; Timmerman H
    Br J Pharmacol; 1995 Oct; 116(4):2315-21. PubMed ID: 8564266
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models.
    Medhurst AD; Atkins AR; Beresford IJ; Brackenborough K; Briggs MA; Calver AR; Cilia J; Cluderay JE; Crook B; Davis JB; Davis RK; Davis RP; Dawson LA; Foley AG; Gartlon J; Gonzalez MI; Heslop T; Hirst WD; Jennings C; Jones DN; Lacroix LP; Martyn A; Ociepka S; Ray A; Regan CM; Roberts JC; Schogger J; Southam E; Stean TO; Trail BK; Upton N; Wadsworth G; Wald JA; White T; Witherington J; Woolley ML; Worby A; Wilson DM
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1032-45. PubMed ID: 17327487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Search for novel leads for histamine H3-receptor antagonists: oxygen-containing derivatives.
    Stark H; Hüls A; Ligneau X; Arrang JM; Schwartz JC; Schunack W
    Pharmazie; 1997 Jul; 52(7):495-500. PubMed ID: 9266588
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of clozapine on rat striatal muscarinic receptors coupled to inhibition of adenylyl cyclase activity and on the human cloned m4 receptor.
    Olianas MC; Maullu C; Onali P
    Br J Pharmacol; 1997 Oct; 122(3):401-8. PubMed ID: 9351494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Piperidine-containing histamine H3 receptor antagonists of the carbamate series: the influence of the additional ether functionality.
    Łazewska D; Kieć-Kononowicz K; Pertz HH; Elz S; Stark H; Schunack W
    Pharmazie; 2002 Dec; 57(12):791-5. PubMed ID: 12561236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The histamine H3 receptor antagonist clobenpropit enhances GABA release to protect against NMDA-induced excitotoxicity through the cAMP/protein kinase A pathway in cultured cortical neurons.
    Dai H; Fu Q; Shen Y; Hu W; Zhang Z; Timmerman H; Leurs R; Chen Z
    Eur J Pharmacol; 2007 Jun; 563(1-3):117-23. PubMed ID: 17350613
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High antagonist potency of GT-2227 and GT-2331, new histamine H3 receptor antagonists, in two functional models.
    Tedford CE; Hoffmann M; Seyedi N; Maruyama R; Levi R; Yates SL; Ali SM; Phillips JG
    Eur J Pharmacol; 1998 Jun; 351(3):307-11. PubMed ID: 9721022
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lack of cataleptogenic potentiation with non-imidazole H3 receptor antagonists reveals potential drug-drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs.
    Zhang M; Ballard ME; Pan L; Roberts S; Faghih R; Cowart M; Esbenshade TA; Fox GB; Decker MW; Hancock AA; Rueter LE
    Brain Res; 2005 May; 1045(1-2):142-9. PubMed ID: 15910772
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histamine homologues discriminating between two functional H3 receptor assays. Evidence for H3 receptor heterogeneity?
    Leurs R; Kathmann M; Vollinga RC; Menge WM; Schlicker E; Timmerman H
    J Pharmacol Exp Ther; 1996 Mar; 276(3):1009-15. PubMed ID: 8786529
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological characterization of GT-2016, a non-thiourea-containing histamine H3 receptor antagonist: in vitro and in vivo studies.
    Tedford CE; Yates SL; Pawlowski GP; Nalwalk JW; Hough LB; Khan MA; Phillips JG; Durant GJ; Frederickson RC
    J Pharmacol Exp Ther; 1995 Nov; 275(2):598-604. PubMed ID: 7473144
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis, and structure-activity relationships of novel non-imidazole histamine H(3) receptor antagonists.
    Linney ID; Buck IM; Harper EA; Kalindjian SB; Pether MJ; Shankley NP; Watt GF; Wright PT
    J Med Chem; 2000 Jun; 43(12):2362-70. PubMed ID: 10882362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.